Yunzhou Biotech received a Series C investment of 410 million yuan to accelerate the global life science and gene drug research and development process

GUANGZHOU, Oct.
11, 2022 /PRNewswire/ -- Yunzhou Biotechnology (Guangzhou) Co.
, Ltd.
(Yunzhou), a leader in gene delivery, recently announced the completion of a Series C financing
of RMB 410 million.
This round of financing was led by Legend Capital, Suikai Investment, Yuexiu Industrial Fund, and C&D Emerging Investment, Wanlian Securities, Guangzhou Property Investment Capital, Jingtingshan Venture Capital, etc.
participated in this round of investment
.
After this round of financing, Yunzhou Biotech will continue to promote the upgrading and capacity expansion of the R&D and production technology platform for gene delivery, increase brand communication and marketing efforts to further accelerate the global business layout, and boost the research and development
of global life sciences and gene drugs.

Yunzhou Biotech is a leading gene delivery enterprise founded by Dr.
Lan Tian, a world-renowned molecular biologist, former tenured professor at the University of Chicago and a researcher at the Howard Hughes School of Medicine (HHMI), providing scientific research and clinical vector CRO, gene drug CDMO and gene delivery property rights export services, covering the entire life science and gene medicine fields
。 Yunzhou Biotech has more than 10 branches and offices around the world, 90% of its business comes from overseas, covering more than 80 countries and regions around the world, and has provided more than 1.
2 million gene delivery solutions to more than 4,000 scientific research institutes and pharmaceutical companies around the world, and gene drug CRO and CDMO projects are spread throughout North America, Europe, Japan and South Korea
.

Open the era of commercialization of personalized gene carriers and help Chinese gene drugs achieve "corner overtaking"

In view of the problems of low efficiency, long time consuming and high cost of vector construction faced by hundreds of thousands of life science laboratories around the world, Yunzhou Biotech's world's first online vector intelligent design platform "VectorBuilder", combined with the offline high-throughput intelligent production management platform, enables highly personalized carriers to achieve large-scale and standardized industrial production, greatly improving efficiency and saving costs
.
The innovation of Yunzhou Biologics from 0 to 1 has opened the era of commercialization of personalized gene vectors and contributed important value
to the acceleration of global life science research.

Gene delivery is a key link in the development of gene drugs, and the current global gene drug industry is in a relatively early stage, which is an important track and key opportunity
for China to achieve "corner overtaking" in the biomedical industry.
In the clinical carrier CRO and gene drug CDMO sector, Yunzhou Biotech helps gene drug companies accelerate the drug cycle and empower the research and development and clinical application
of gene drugs with its core technology research and development and production capabilities.

Dr.
Lantian Lin, founder and chief scientist of Yunzhou Biotechnology, said: "We are very grateful to the investors for their support
to Yunzhou Biotechnology.
We have a very strong technology accumulation and excellent business model in the gene delivery industry, and have occupied the highest market share in the global gene vector research market, and in April this year, we launched the construction
of a 45,000㎡ gene delivery R&D and production base in Guangzhou Development Zone.
We hope to take this round of financing as an opportunity to further accelerate the comprehensive upgrading and optimization of the technology platform, promote the expansion of production capacity, and increase the global layout to empower basic scientific research, accelerate the clinical application of gene drugs, and become a leading enterprise
in the entire industry chain of gene delivery.
" In the future, Yunzhou Biotech will enter thousands of life science laboratories around the world, become a household name in the field of life sciences, empower the gene drug industry through core technologies, and help China 'overtake' in the gene drug track.
"
At the same time, we hope to overcome genetic diseases, improve human health, and provide irreplaceable value
to the industry and the world.
”

Technological innovation and business models are difficult to replicate, and are leading the gene delivery revolution

Wang Jianfei, Managing Director of Legend Capital, said: "Yunzhou Biotech is a leading global gene delivery company, providing full-chain solutions
from basic scientific research to clinical application gene delivery 。 We are optimistic about Dr.
Lan Zhou's leadership to create a comprehensive ecological service platform for gene delivery needs in life sciences and biomedicine, the company has developed the world's first online design, offline production vector construction and downstream application service system, serving thousands of top biopharmaceutical companies and research institutes
.
With the development of the gene drug industry, Yunzhou Biotech can look forward to
the future.
”

Zhang Xiaozhong, Chairman of Guangzhou Development Zone Investment Group, said: "Yunzhou Biotech has created an era of commercialization of customized gene carriers, under the leadership of Dr.
Lantian, global performance has grown rapidly, and the superposition of technology research and development and business model innovation has made the company extremely scarce in the imaginative gene therapy track, which is difficult to be replicated
.
Kai Investment Group has been accompanying the growth and development of
Yunzhou Biology for a long time.
Leading the investment again, we are very much looking forward to Yunzhou Biotech promoting the gene therapy industry chain supplement chain and strengthening chain project in the Guangzhou Development Zone, helping China to achieve 'corner overtaking' in the gene drug track and giving birth to a global leader
.
" ”

Lu Rong, Managing Partner and President of Yuexiu Industrial Fund, said: "With the rapid development of global cell and gene therapy, it is expected to become the third largest biomedical pillar industry
after small molecule targeted drugs and large molecule biological drugs.
Yunzhou Biotech takes 'carrier home' as the entry point, provides customers with full-chain solutions for gene delivery in the stage from basic scientific research to clinical application, and is the world's leading gene delivery service enterprise
.
The founder, Dr.
Lam Tian, is an internationally renowned geneticist with more than 30 years of experience
in the field of genetics.
We are very pleased to lead Yunzhou Biotech and believe that under the leadership of Dr.
Lantian Yunzhou Biotechnology will continue to develop
rapidly.
At the same time, it is believed that with the collaboration of Yunzhou Biotechnology, Guangzhou will gradually become a gathering place for cell and gene therapy enterprises, gradually form an industrial ecosystem, and provide assistance
for Guangzhou to build a world-class biomedical industry cluster.
”